Business Context and Reporting Period
This Form 8-K is a current report filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) on September 12, 2025. The filing discloses the entry into a material definitive agreement regarding the appointment of an Interim Chief Executive Officer.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the compensation arrangement for the new executive:
- Executive Compensation: $12,500 per month for the Interim CEO.
Material Changes
The primary material change reported is the formalization of the leadership appointment previously announced on September 9, 2025:
- Executive Appointment: Jason D. Sawyer was appointed as Interim Chief Executive Officer.
- Agreement Details: A consulting agreement was entered into on September 8, 2025, effective retroactively to September 4, 2025.
- Indemnification: The company agreed to defend and indemnify Mr. Sawyer to the fullest extent permitted under Delaware General Corporation Law.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The document focuses solely on the contractual terms of the CEO agreement. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full text of the Consulting Agreement (Exhibit 10.1) for termination clauses, equity incentives, or additional compensation not summarized in the 8-K.
- Confirm the status of the previous CEO and the timeline for a permanent appointment, as Mr. Sawyer is currently Interim.
- Review the company's cash position to ensure it can sustain the new monthly executive compensation alongside existing operational costs.
- Check for any subsequent filings regarding the transition from interim to permanent leadership.